Noninvasive prediction of Clinically Significant Portal Hypertension (CSPH) can be pivotal for liver function diagnosis and monitoring. Because CSPH is the most common liver indication that accounts for significant levels of morbidity and mortality, Exalenz is committed to revolutionize CSPH diagnostic procedures. The standard clinical test, Hepatic Venous Pressure Gradient (HVPG), is highly expensive and markedly invasive, requiring local anesthesia, exposure to radiation, and the use of contrast material that may harm the kidneys. Moreover, it requires professional skill and financial resources unavailable in most medical centers.
BreathID® testing for CSPH has been studied in Europe and the USA and proven to be an effective alternative for traditional CSPH diagnosis. Simple and safe, the BreathID® noninvasive diagnostic test was found reliably accurate and precise, while also highly cost-effective compared with invasive HVPG. BreathID® offers the ultimate advantage of enabling more patients to be diagnosed and treated rapidly and with reduced healthcare costs.
Study of World’s First Breath-Based Test to Diagnose Clinically Significant Portal Hypertension
Exalenz conducted a multinational study in Europe and the U.S. to diagnose Clinically Significant Portal Hypertension (CSPH). The two-stage multinational study was conducted in leading American and European medical centers. Data was collected for 200 patients and used for developing an advanced index algorithm that compares BreathID® and HVPG.
Validation study is planned to be executed in 2017.